Towson, Maryland Clinical Trials

A listing of Towson, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 126 clinical trials
A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy

This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus atezolizumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

malignant melanoma of skin
immunomodulators
cobimetinib
NRAS
immunologic adjuvant
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
 (7.6 away) Contact site
  • 1 views
  • 16 Oct, 2022
  • +23 other locations
A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination With Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03) (DL03)

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with durvalumab and chemotherapy in patients with HER2 positive advanced and metastatic non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.

Research Site
 (7.8 away) Contact site
  • 16 views
  • 17 Oct, 2022
  • +39 other locations
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers (EMBER)

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

metastasis
EGFR
immunostimulant
abemaciclib
stage iv breast cancer
Johns Hopkins University
 (7.6 away) Contact site
  • 238 views
  • 22 Oct, 2022
  • +75 other locations
A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine …

metastasis
immunomodulators
arginine
gemcitabine
IDH2
The John Hopkins Hospital
 (7.6 away) Contact site
  • 14 views
  • 20 Oct, 2022
  • +34 other locations
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

A study to assess the safety, tolerability, and pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer

metastasis
platinum-based chemotherapy
brain metastases
cancer chemotherapy
pembrolizumab
John Hopkins Sidney Kimmel Comprehensive Cancer Center
 (7.6 away) Contact site
  • 416 views
  • 21 Oct, 2022
  • +33 other locations
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

This trial will evaluate long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

primary cancer
GSK Investigational Site
 (7.7 away) Contact site
  • 0 views
  • 07 Oct, 2022
  • +35 other locations
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.

lymphoma
BRAF
sarcoma
ROS1
primary cancer
GSK Investigational Site
 (8.6 away) Contact site
  • 0 views
  • 07 Oct, 2022
  • +18 other locations
A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or …

Johns Hopkins University /ID# 201320
 (7.6 away) Contact site
  • 562 views
  • 27 Oct, 2022
  • +34 other locations
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors (STELLAR-001)

This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

metastasis
EGFR
solid tumour
transitional cell carcinoma
carboplatin
Exelixis Clinical Site #44
 (7.7 away) Contact site
  • 32 views
  • 28 Oct, 2022
  • +60 other locations
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that have progressed despite standard therapy or for which no effective standard therapy exists

metastasis
malignant melanoma of skin
squamous cell carcinoma of head and neck
immunomodulators
BRAF
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins
 (7.7 away) Contact site
  • 1231 views
  • 29 Oct, 2022
  • +14 other locations